1257. Re-Evaluation of Cefepime or Piperacillin-Tazobactam to Decrease Use of Carbapenems in ESBL-Producing Enterobacterales Urinary Tract Infections (REDUCE-UTI)

BACKGROUND: Carbapenems (CBP) are considered first-line for infections caused by extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E). However, recent literature suggests that cefepime (FEP) and piperacillin-tazobactam (TZP) may produce similar outcomes vs. CBPs for the treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales: Branton, Alexander C, Vu, Catherine H, Veena, Venugopalan, Santevecchi, Barbara A, Ramphal, Reuben, Cherabuddi, Kartikeya, Manohar, Tanvi, Rodriguez, David, Tello, Andrea, DeSear, Kathryn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643863/
http://dx.doi.org/10.1093/ofid/ofab466.1449

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643863/
http://dx.doi.org/10.1093/ofid/ofab466.1449

Ejemplares similares